Endocyte receives $26M infusion from investors

Back to TopCommentsE-mailPrintBookmark and Share

West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company continue developing cancer-fighting drugs.

The latest round of financing included participation from all the company's prior institutional investors: Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co. and Triathlon Medical Ventures.

Clarian Health Ventures, the Indianapolis-based hospital system’s $25 million venture capital fund, also participated as a new investor.

“Our investors recognize the important clinical and pre-clinical progress we have made, as well as the significant potential of these technologies,” said Mike Sherman, Endocyte’s chief financial officer, in a written statement.

The company has a pipeline of drugs in development for the treatment of various cancers and inflammatory diseases, including six cancer drugs in clinical trials.

At the World Conference on Lung Cancer in San Francisco in August, Endocyte announced positive results for its lead drug, EC145, in a Phase II non-small cell lung cancer study.

The company also announced, at the annual meeting of the European Society of Gynecologic Oncology that ended Thursday, positive preliminary results for the same drug in a Phase II ovarian cancer study.

Endocyte is headquartered at Purdue University Research Park.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ